

ASX ANNOUNCEMENT

Entitlement Offer raises \$913,000

5 June 2019 – Brisbane, Australia – Analytica Limited (ASX:ALT) (Company) is pleased to announce that it has completed its 1 for 6 pro-rata, non-renounceable entitlement offer announced on 10 May 2019 (**Entitlement Offer**).

The Entitlement Offer opened on Monday, 20 May 2019 and closed at 5:00pm (Sydney time) on Friday, 31 May 2019.

The total number of new shares offered under the Entitlement Offer was 556,168,725. The Entitlement Offer has been well supported by shareholders, with shareholders applying for 182,599,982 shares raising approximately \$913,000. Accordingly, the shortfall was 373,568,743 shares.

The Entitlement Offer was strongly supported by the Board, with Dr Monsour applying for 102,832,611 shares (\$514,163) and Mr Mangelsdorf applying for 9,000,000 shares (\$45,000).

The shares to be issued under the Entitlement Offer are expected to be issued on Friday, 7 June 2019, with normal trading of new shares to commence on Tuesday, 11 June 2019.

Directors would like to thank the shareholders who participated in the Entitlement Offer

Bryan Dulhunty
Company Secretary.

For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

Follow us on:    


About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance for urinary incontinence in Australia and has CE mark and USFDA 510(k) clearance.





PeriCoach also has clearance in Australia, and CE Marking in Europe for the treatment of pelvic organ prolapse, a condition that affects up to 1 in 5 women during their lifetime.

The product is available for sale from pericoach.com in Australia, New Zealand, UK and Ireland, and the USA.